We are live on ! Find out more
AQST icon

Aquestive Therapeutics

44 hedge funds and large institutions have $282M invested in Aquestive Therapeutics in 2018 Q3 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

64.5% more ownership

Funds ownership: 0%64.5% (+64%)

Holders
44
Holders Change
+44
Holders Change %
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
44
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

AQST Hedge Fund Activity: Q3 2018 in Review

44 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2018, worth a combined $282M.

Buyers outnumbered sellers: 44 funds opened new AQST positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Crestline Management, opening a new position worth an estimated $190M.

  • 44 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $282M of Aquestive Therapeutics stock for Q3 2018.
  • 44 funds opened new Aquestive Therapeutics positions in Q3 2018 and 0 closed out, a net change of +44 holders.
  • The largest Aquestive Therapeutics buyer in Q3 2018 was Crestline Management, an estimated $190M added.

Based on aggregated 13F filings for Q3 2018.